Skip to content
2000
image of Post-marketing Safety Surveillance of Drug-induced Dementia: Utilizing Signal Detection and Mendelian Randomization in Spontaneous Reports

Abstract

Objective

Many medications associated with an increased risk of dementia do not have adequate warning labels, leading to a significant underestimation of their potential dangers. This study aims to leverage the FAERS database to identify drugs strongly linked to dementia and to examine the relationship between these drugs using Mendelian randomization techniques. The ultimate goal is to mitigate the risk of developing dementia.

Methods

We utilized the FAERS database to identify medications significantly associated with dementia cases. The DrugBank, OpenTargets, and STITCH databases were employed to pinpoint the target genes of these drugs. We then conducted Mendelian randomization analysis to explore the correlation between the expression of drug target genes and the incidence of dementia. Additionally, a time-to-onset analysis assessed the temporal relationships of drug ingestions. Furthermore, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Protein-Protein Interaction Network (PPI) analyses were performed to investigate the molecular pathways linked to target genes related to drugs associated with dementia.

Results

A total of 28,139 dementia events were recorded in the FAERS database. Our Mendelian randomization analysis revealed a significant association between the expression of all identified drug target genes and dementia in both blood and brain tissues. Specifically, we identified nine drug target genes with significant correlations, implicating quetiapine, clozapine, valproic acid, alendronate, and digoxin as being strongly associated with dementia, which could provide insight into areas of clinical concern regarding dementia occurrence.

Conclusion

The adverse event data sourced from the FAERS database indicate that certain medications are associated with an increased risk of developing dementia, a finding corroborated by our Mendelian randomization analysis. Establishing a comprehensive monitoring and risk assessment program is crucial for identifying high-risk individuals and facilitating informed medication choices, thereby potentially reducing the incidence of dementia.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673378809250707043350
2025-08-12
2025-11-04

  • From This Site

    /content/journals/cmc/10.2174/0109298673378809250707043350
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Baumgart M. Snyder H.M. Carrillo M.C. Fazio S. Kim H. Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimers Dement. 2015 11 6 718 726 10.1016/j.jalz.2015.05.016 26045020
    [Google Scholar]
  2. Prince M. Bryce R. Albanese E. Wimo A. Ribeiro W. Ferri C.P. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement. 2013 9 1 63 75.e2 10.1016/j.jalz.2012.11.007 23305823
    [Google Scholar]
  3. Langan S.J. Deary I.J. Hepburn D.A. Frier B.M. Cumulative cognitive impairment following recurrent severe hypoglycaemia in adult patients with insulin-treated diabetes mellitus. Diabetologia 1991 34 5 337 344 10.1007/BF00405006 1864488
    [Google Scholar]
  4. Ghosh S.K. Letter: Methyldopa and forgetfulness. Lancet 1976 307 7952 202 203 10.1016/S0140‑6736(76)91318‑0
    [Google Scholar]
  5. Denicoff K.D. Rubinow D.R. Papa M.Z. Simpson C. Seipp C.A. Lotze M.T. Chang A. Rosenstein D. Rosenberg S.A. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann. Intern. Med. 1987 107 3 293 300 10.7326/0003‑4819‑107‑2‑293 3497595
    [Google Scholar]
  6. Yu R.J. Krantz M.S. Phillips E.J. Stone C.A. Jr. Emerging causes of drug-induced anaphylaxis: A review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS). J. Allergy Clin. Immunol. Pract. 2021 9 2 819 829.e2 10.1016/j.jaip.2020.09.021 32992044
    [Google Scholar]
  7. Zhou C. Peng S. Lin A. Jiang A. Peng Y. Gu T. Liu Z. Cheng Q. Zhang J. Luo P. Psychiatric disorders associated with immune checkpoint inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. EClinicalMedicine 2023 59 101967 10.1016/j.eclinm.2023.101967 37131541
    [Google Scholar]
  8. Yin Y. Shu Y. Zhu J. Li F. Li J. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib. Sci. Rep. 2022 12 1 19555 10.1038/s41598‑022‑23834‑1 36380085
    [Google Scholar]
  9. Anand K. Ensor J. Trachtenberg B. Bernicker E.H. Osimertinib-induced cardiotoxicity. JACC: CardioOncology 2019 1 2 172 178 10.1016/j.jaccao.2019.10.006 34396179
    [Google Scholar]
  10. Ahdi H.S. Wichelmann T.A. Pandravada S. Ehrenpreis E.D. Medication-induced osteonecrosis of the jaw: A review of cases from the food and drug administration adverse event reporting system (FAERS). BMC Pharmacol. Toxicol. 2023 24 1 15 10.1186/s40360‑023‑00657‑y 36879299
    [Google Scholar]
  11. Larsson S.C. Butterworth A.S. Burgess S. Mendelian randomization for cardiovascular diseases: Principles and applications. Eur. Heart J. 2023 44 47 4913 4924 10.1093/eurheartj/ehad736 37935836
    [Google Scholar]
  12. Ho J. Mak C. Sharma V. To K. Khan W. Mendelian randomization studies of lifestyle-related risk factors for osteoarthritis: A PRISMA review and meta-analysis. Int. J. Mol. Sci. 2022 23 19 11906 10.3390/ijms231911906 36233208
    [Google Scholar]
  13. Emdin C.A. Khera A.V. Kathiresan S. Mendelian randomization. JAMA 2017 318 19 1925 1926 10.1001/jama.2017.17219 29164242
    [Google Scholar]
  14. Liu Y. Lai H. Zhang R. Xia L. Liu L. Causal relationship between gastro-esophageal reflux disease and risk of lung cancer: Insights from multivariable mendelian randomization and mediation analysis. Int. J. Epidemiol. 2023 52 5 1435 1447 10.1093/ije/dyad090 37344162
    [Google Scholar]
  15. Yang M. Wan X. Zheng H. Xu K. Xie J. Yu H. Wang J. Xu P. No evidence of a genetic causal relationship between ankylosing spondylitis and gut microbiota: A two-sample mendelian randomization study. Nutrients 2023 15 4 1057 10.3390/nu15041057 36839415
    [Google Scholar]
  16. Davey Smith G. Hemani G. Mendelian randomization: Genetic anchors for causal inference in epidemiological studies. Hum. Mol. Genet. 2014 23 R1 R89 R98 10.1093/hmg/ddu328 25064373
    [Google Scholar]
  17. Burgess S. Scott R.A. Timpson N.J. Davey Smith G. Thompson S.G. EPIC- InterAct Consortium Using published data in mendelian randomization: A blueprint for efficient identification of causal risk factors. Eur. J. Epidemiol. 2015 30 7 543 552 10.1007/s10654‑015‑0011‑z 25773750
    [Google Scholar]
  18. Feng Z. Zhao Q. Wu J. Yang Y. Jia X. Ma J. Tang H. Yuan H. Yang G. Lu Y. Nonselective beta-adrenoceptor blocker use and risk of Parkinson’s disease: From multiple real-world evidence. BMC Med. 2023 21 1 437 10.1186/s12916‑023‑03122‑z 37964359
    [Google Scholar]
  19. Asano H. Tian Y.S. Hatabu A. Takagi T. Ueda M. Ikeda K. Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system. Sci. Rep. 2023 13 1 19272 10.1038/s41598‑023‑44142‑2 37935702
    [Google Scholar]
  20. Artusi C.A. Sarro L. Imbalzano G. Fabbri M. Lopiano L. Safety and efficacy of tolcapone in Parkinson’s disease: Systematic review. Eur. J. Clin. Pharmacol. 2021 77 6 817 829 10.1007/s00228‑020‑03081‑x 33415500
    [Google Scholar]
  21. Raschi E. Antonazzo I.C. La Placa M. Ardizzoni A. Poluzzi E. De Ponti F. Serious cutaneous toxicities with immune checkpoint inhibitors in the U.S. food and drug administration adverse event reporting system. Oncologist 2019 24 11 e1228 e1231 10.1634/theoncologist.2019‑0250 31387950
    [Google Scholar]
  22. Raschi E. La Placa M. Poluzzi E. De Ponti F. The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice. Br. J. Dermatol. 2021 184 3 581 583 10.1111/bjd.19677 33184850
    [Google Scholar]
  23. Yang Z. Lv Y. Yu M. Mei M. Xiang L. Zhao S. Li R. GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS. Front. Pharmacol. 2022 13 925377 10.3389/fphar.2022.925377 36386208
    [Google Scholar]
  24. Chen Y. Fan Q. Liu Y. Shi Y. Luo H. Cardiovascular toxicity induced by SSRIs: Analysis of spontaneous reports submitted to FAERS. Psychiatry Res. 2023 326 115300 10.1016/j.psychres.2023.115300 37364503
    [Google Scholar]
  25. Zheng H. Shi Y.Z. Liang J.T. Lu L.L. Chen M. Modifiable factors for migraine prophylaxis: A mendelian randomization analysis. Front. Pharmacol. 2023 14 1010996 10.3389/fphar.2023.1010996 36713835
    [Google Scholar]
  26. Hemani G. Zheng J. Elsworth B. Wade K.H. Haberland V. Baird D. Laurin C. Burgess S. Bowden J. Langdon R. Tan V.Y. Yarmolinsky J. Shihab H.A. Timpson N.J. Evans D.M. Relton C. Martin R.M. Davey Smith G. Gaunt T.R. Haycock P.C. The MR-Base platform supports systematic causal inference across the human phenome. eLife 2018 7 34408 10.7554/eLife.34408 29846171
    [Google Scholar]
  27. Meng Z. Ma Y. Li W. Deng X. Association between periodontitis and COVID-19 infection: A two-sample mendelian randomization study. PeerJ 2023 11 14595 10.7717/peerj.14595 36718446
    [Google Scholar]
  28. Yuan J.X. Jiang Q. Yu S.J. Diabetes mellitus and prostate cancer risk: A mendelian randomization analysis. World J. Diabetes 2023 14 12 1839 1848 10.4239/wjd.v14.i12.1839 38222791
    [Google Scholar]
  29. Yang M. Su Y. Xu K. Wen P. Zhang B. Guo J. Nan K. Yang P. Shao X. Liu L. Yang Z. Xu P. Common autoimmune diseases and urticaria: The causal relationship from a bidirectional two-sample mendelian randomization study. Front. Immunol. 2023 14 1280135 10.3389/fimmu.2023.1280135 38022623
    [Google Scholar]
  30. Kurki M.I. Karjalainen J. Palta P. Sipilä T.P. Kristiansson K. Donner K.M. Reeve M.P. Laivuori H. Aavikko M. Kaunisto M.A. Loukola A. Lahtela E. Mattsson H. Laiho P. Della Briotta Parolo P. Lehisto A.A. Kanai M. Mars N. Rämö J. Kiiskinen T. Heyne H.O. Veerapen K. Rüeger S. Lemmelä S. Zhou W. Ruotsalainen S. Pärn K. Hiekkalinna T. Koskelainen S. Paajanen T. Llorens V. Gracia-Tabuenca J. Siirtola H. Reis K. Elnahas A.G. Sun B. Foley C.N. Aalto-Setälä K. Alasoo K. Arvas M. Auro K. Biswas S. Bizaki-Vallaskangas A. Carpen O. Chen C.Y. Dada O.A. Ding Z. Ehm M.G. Eklund K. Färkkilä M. Finucane H. Ganna A. Ghazal A. Graham R.R. Green E.M. Hakanen A. Hautalahti M. Hedman Å.K. Hiltunen M. Hinttala R. Hovatta I. Hu X. Huertas-Vazquez A. Huilaja L. Hunkapiller J. Jacob H. Jensen J.N. Joensuu H. John S. Julkunen V. Jung M. Junttila J. Kaarniranta K. Kähönen M. Kajanne R. Kallio L. Kälviäinen R. Kaprio J. Kerimov N. Kettunen J. Kilpeläinen E. Kilpi T. Klinger K. Kosma V.M. Kuopio T. Kurra V. Laisk T. Laukkanen J. Lawless N. Liu A. Longerich S. Mägi R. Mäkelä J. Mäkitie A. Malarstig A. Mannermaa A. Maranville J. Matakidou A. Meretoja T. Mozaffari S.V. Niemi M.E.K. Niemi M. Niiranen T. O´Donnell C.J. Obeidat M. Okafo G. Ollila H.M. Palomäki A. Palotie T. Partanen J. Paul D.S. Pelkonen M. Pendergrass R.K. Petrovski S. Pitkäranta A. Platt A. Pulford D. Punkka E. Pussinen P. Raghavan N. Rahimov F. Rajpal D. Renaud N.A. Riley-Gillis B. Rodosthenous R. Saarentaus E. Salminen A. Salminen E. Salomaa V. Schleutker J. Serpi R. Shen H. Siegel R. Silander K. Siltanen S. Soini S. Soininen H. Sul J.H. Tachmazidou I. Tasanen K. Tienari P. Toppila-Salmi S. Tukiainen T. Tuomi T. Turunen J.A. Ulirsch J.C. Vaura F. Virolainen P. Waring J. Waterworth D. Yang R. Nelis M. Reigo A. Metspalu A. Milani L. Esko T. Fox C. Havulinna A.S. Perola M. Ripatti S. Jalanko A. Laitinen T. Mäkelä T.P. Plenge R. McCarthy M. Runz H. Daly M.J. Palotie A. FinnGen FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 2023 613 7944 508 518 10.1038/s41586‑022‑05473‑8 36653562
    [Google Scholar]
  31. Luo J. Xu Z. Noordam R. van Heemst D. Li-Gao R. Depression and inflammatory bowel disease: A bidirectional two-sample mendelian randomization study. J. Crohn’s Colitis 2022 16 4 633 642 10.1093/ecco‑jcc/jjab191 34739073
    [Google Scholar]
  32. Zou X. Wang L. Wang S. Zhang Y. Ma J. Chen L. Li Y. Yao T.X. Zhou H. Wu L. Tang Q. Ma S. Zhang X. Tang R. Yi Y. Liu R. Zeng Y. Zhang L. Promising therapeutic targets for ischemic stroke identified from plasma and cerebrospinal fluid proteomes: A multicenter mendelian randomization study. Int. J. Surg. 2023 110 2 766 776 10.1097/JS9.0000000000000922 38016292
    [Google Scholar]
  33. Yuan Z. Kang Y. Mo C. Huang S. Qin F. Zhang J. Wang F. Jiang J. Yang X. Liang H. Ye L. Causal relationship between gut microbiota and tuberculosis: A bidirectional two-sample mendelian randomization analysis. Respir. Res. 2024 25 1 16 10.1186/s12931‑023‑02652‑7 38178098
    [Google Scholar]
  34. He Z. Lam K. Zhao W. Yang S. Li Y. Mo J. Gao S. Liang D. Qiu K. Huang M. Wu J. SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: A pharmacovigilance assessment. Acta Diabetol. 2022 60 3 401 411 10.1007/s00592‑022‑02015‑6 36576563
    [Google Scholar]
  35. Abulizi A. Yan G. Xu Q. Muhetaer R. Wu S. Abudukelimu K. Chen X. Liu C. Li J. Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC). Sci. Rep. 2024 14 1 25919 10.1038/s41598‑024‑75099‑5 39472591
    [Google Scholar]
  36. Xu M. Zhang X. Cao J. Liu J. He Y. Guan Q. Tian X. Tang J. Li X. Ren D. Bu Q. Wang Z. OsPGL3A encodes a DYW-type pentatricopeptide repeat protein involved in chloroplast RNA processing and regulated chloroplast development. Mol. Breed. 2024 44 4 29 10.1007/s11032‑024‑01468‑7 38549701
    [Google Scholar]
  37. Tian X. Chen L. Gai D. He S. Jiang X. Zhang N. Adverse event profiles of PARP inhibitors: Analysis of spontaneous reports submitted to FAERS. Front. Pharmacol. 2022 13 851246 10.3389/fphar.2022.851246 35401230
    [Google Scholar]
  38. Kinoshita S. Hosomi K. Yokoyama S. Takada M. Time-to-onset analysis of amiodarone-associated thyroid dysfunction. J. Clin. Pharm. Ther. 2020 45 1 65 71 10.1111/jcpt.13024 31400296
    [Google Scholar]
  39. Ledda C. Artusi C.A. Tribolo A. Rinaldi D. Imbalzano G. Lopiano L. Zibetti M. Time to onset and duration of botulinum toxin efficacy in movement disorders. J. Neurol. 2022 269 7 3706 3712 10.1007/s00415‑022‑10995‑2 35113259
    [Google Scholar]
  40. Sato K. Niimi Y. Mano T. Iwata A. Iwatsubo T. Time to onset of drug-induced Parkinsonism: Analysis using a large Japanese adverse event self-reporting database. Biosci. Trends 2022 16 2 151 157 10.5582/bst.2022.01115 35444114
    [Google Scholar]
  41. Mazhar F. Battini V. Gringeri M. Pozzi M. Mosini G. Marran A.M.N. Akram S. van Manen R.P. Radice S. Clementi E. Carnovale C. The impact of anti-TNFα agents on weight-related changes: New insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database. Expert Opin. Biol. Ther. 2021 21 9 1281 1290 10.1080/14712598.2021.1948529 34191656
    [Google Scholar]
  42. Wang J. Zhang Z. Liu X. Shi S. Lv J. Zhang Y. Zhang H. Exploring novel adverse events of nefecon. Kidney Int. Rep. 2024 9 9 2705 2717 10.1016/j.ekir.2024.07.006 39291217
    [Google Scholar]
  43. Yang X. Zheng X. Zhang M. Huang J. Huang P. Wang J. Drug-induced gynecomastia: Data mining and analysis of the FDA adverse event reporting system database. Clin. Epidemiol. 2024 16 617 630 10.2147/CLEP.S470959 39280118
    [Google Scholar]
  44. Hasegawa S. Matsui T. Hane Y. Abe J. Hatahira H. Motooka Y. Sasaoka S. Fukuda A. Naganuma M. Hirade K. Takahashi Y. Kinosada Y. Nakamura M. Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese adverse drug event report database. PLoS One 2017 12 7 0182045 10.1371/journal.pone.0182045 28732067
    [Google Scholar]
  45. Ohyama K. Iida M. Akiyama S. Yamazaki H. Hori Y. Time-to-onset analysis of rhabdomyolysis due to different proton pump inhibitors using a pharmacovigilance database. In Vivo 2024 38 3 1285 1291 10.21873/invivo.13567 38688634
    [Google Scholar]
  46. Takigawa M. Tanaka H. Washiashi H. Onoda T. Ishigami A. Ishii T. Time to onset of gemcitabine-induced thrombotic microangiopathy in a Japanese population: A case series and large-scale pharmacovigilance analysis. Cancer Diagnosis & Prognosis 2022 3 1 115 123 10.21873/cdp.10188 36632593
    [Google Scholar]
  47. Komada F. Nakayama Y. Takara K. Analysis of time- to-onset and onset-pattern of interstitial lung disease after the administration of monoclonal antibody agents. Yakugaku Zasshi 2018 138 12 1587 1594 10.1248/yakushi.18‑00094 30504674
    [Google Scholar]
  48. Zou D. Zhang R. Yu L. Hu T. Wu B. Seizures associated with antibiotics: A real-world disproportionality analysis of FAERS database. Expert Opin. Drug Saf. 2023 22 11 1143 1148 10.1080/14740338.2023.2234825 37417744
    [Google Scholar]
  49. Liu Y. Li H. Hu C. Tan L. Yin P. Li Z. Zhou S. Su L. A real-world pharmacovigilance analysis for transthyretin inhibitors: Findings from the FDA adverse event reporting database. Front. Pharmacol. 2024 15 1368244 10.3389/fphar.2024.1368244 38873427
    [Google Scholar]
  50. Huang H. Hu C. Liu F. Ji F. Fu Y. Cao M. Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: A pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system. Br. J. Anaesth. 2024 134 5 1486 1496 10.1016/j.bja.2024.10.013 39578156
    [Google Scholar]
  51. Hatahira H. Abe J. Hane Y. Matsui T. Sasaoka S. Motooka Y. Hasegawa S. Fukuda A. Naganuma M. Ohmori T. Kinosada Y. Nakamura M. Drug-induced gingival hyperplasia: A retrospective study using spontaneous reporting system databases. J. Pharm. Health Care Sci. 2017 3 1 19 10.1186/s40780‑017‑0088‑5 28729910
    [Google Scholar]
  52. Wang Y. Yao Y. Hu J. Lin Y. Cai C. Zhao Y. Development of a predictive nomogram for estimating medication nonadherence in hemodialysis patients. Med. Sci. Monit. 2022 28 934482 10.12659/MSM.934482 35290293
    [Google Scholar]
  53. Davies N.M. Holmes M.V. Davey Smith G. Reading mendelian randomisation studies: A guide, glossary, and checklist for clinicians. BMJ 2018 362 k601 10.1136/bmj.k601 30002074
    [Google Scholar]
  54. Aguet F. Anand S. Ardlie K.G. Gabriel S. Getz G.A. Graubert A. Hadley K. Handsaker R.E. Huang K.H. Kashin S. Li X. MacArthur D.G. Meier S.R. Nedzel J.L. Nguyen D.T. Segrè A.V. Todres E. Balliu B. Barbeira A.N. Battle A. Bonazzola R. Brown A. Brown C.D. Castel S.E. Conrad D.F. Cotter D.J. Cox N. Das S. de Goede O.M. Dermitzakis E.T. Einson J. Engelhardt B.E. Eskin E. Eulalio T.Y. Ferraro N.M. Flynn E.D. Fresard L. Gamazon E.R. Garrido-Martín D. Gay N.R. Gloudemans M.J. Guigó R. Hame A.R. He Y. Hoffman P.J. Hormozdiari F. Hou L. Im H.K. Jo B. Kasela S. Kellis M. Kim-Hellmuth S. Kwong A. Lappalainen T. Li X. Liang Y. Mangul S. Mohammadi P. Montgomery S.B. Muñoz-Aguirre M. Nachun D.C. Nobel A.B. Oliva M. Park Y.S. Park Y. Parsana P. Rao A.S. Reverter F. Rouhana J.M. Sabatti C. Saha A. Stephens M. Stranger B.E. Strober B.J. Teran N.A. Viñuela A. Wang G. Wen X. Wright F. Wucher V. Zou Y. Ferreira P.G. Li G. Melé M. Yeger-Lotem E. Barcus M.E. Bradbury D. Krubit T. McLean J.A. Qi L. Robinson K. Roche N.V. Smith A.M. Sobin L. Tabor D.E. Undale A. Bridge J. Brigham L.E. Foster B.A. Gillard B.M. Hasz R. Hunter M. Johns C. Johnson M. Karasik E. Kopen G. Leinweber W.F. McDonald A. Moser M.T. Myer K. Ramsey K.D. Roe B. Shad S. Thomas J.A. Walters G. Washington M. Wheeler J. Jewell S.D. Rohrer D.C. Valley D.R. Davis D.A. Mash D.C. Branton P.A. Barker L.K. Gardiner H.M. Mosavel M. Siminoff L.A. Flicek P. Haeussler M. Juettemann T. Kent W.J. Lee C.M. Powell C.C. Rosenbloom K.R. Ruffier M. Sheppard D. Taylor K. Trevanion S.J. Zerbino D.R. Abell N.S. Akey J. Chen L. Demanelis K. Doherty J.A. Feinberg A.P. Hansen K.D. Hickey P.F. Jasmine F. Jiang L. Kaul R. Kibriya M.G. Li J.B. Li Q. Lin S. Linder S.E. Pierce B.L. Rizzardi L.F. Skol A.D. Smith K.S. Snyder M. Stamatoyannopoulos J. Tang H. Wang M. Carithers L.J. Guan P. Koester S.E. Little A.R. Moore H.M. Nierras C.R. Rao A.K. Vaught J.B. Volpi S. GTEx Consortium The GTEx consortium atlas of genetic regulatory effects across human tissues. Science 2020 369 6509 1318 1330 10.1126/science.aaz1776 32913098
    [Google Scholar]
  55. Chen X. Kong J. Diao X. Cai J. Zheng J. Xie W. Qin H. Huang J. Lin T. Depression and prostate cancer risk: A mendelian randomization study. Cancer Med. 2020 9 23 9160 9167 10.1002/cam4.3493 33027558
    [Google Scholar]
  56. Zagkos L. Dib M.J. Pinto R. Gill D. Koskeridis F. Drenos F. Markozannes G. Elliott P. Zuber V. Tsilidis K. Dehghan A. Tzoulaki I. Associations of genetically predicted fatty acid levels across the phenome: A mendelian randomisation study. PLoS Med. 2022 19 12 1004141 10.1371/journal.pmed.1004141 36580444
    [Google Scholar]
  57. Wang S. Zhu H. Pan L. Zhang M. Wan X. Xu H. Hua R. Zhu M. Gao P. Systemic inflammatory regulators and risk of acute-on-chronic liver failure: A bidirectional mendelian-randomization study. Front. Cell Dev. Biol. 2023 11 1125233 10.3389/fcell.2023.1125233 36743413
    [Google Scholar]
  58. Yuan S. Larsson S.C. Coffee and caffeine consumption and risk of kidney stones: A mendelian randomization study. Am. J. Kidney Dis. 2022 79 1 9 14.e1 10.1053/j.ajkd.2021.04.018 34690004
    [Google Scholar]
  59. Nie Q. Luo Q. Yan W. Zhang T. Wang H. Wu J. Rheumatoid arthritis and coronary atherosclerosis: A two-sample mendelian randomization study. Front. Cardiovasc. Med. 2023 10 1033644 10.3389/fcvm.2023.1033644 37187788
    [Google Scholar]
  60. Luo Q. Yan W. Nie Q. Han W. Vitamin D and heart failure: A two-sample mendelian randomization study. Nutr. Metab. Cardiovasc. Dis. 2022 32 11 2612 2620 10.1016/j.numecd.2022.08.003 36064684
    [Google Scholar]
  61. Li Z. Zhao Z. Chen S. Wang X. Wang D. Nie X. Yao Y. Ge-Gen-Qin-Lian decoction alleviates the symptoms of type 2 diabetes mellitus with inflammatory bowel disease via regulating the AGE-RAGE pathway. BMC Complementary Medicine and Therapies 2024 24 1 225 10.1186/s12906‑024‑04526‑x 38858747
    [Google Scholar]
  62. Liu P. Liu Z. Luo Q. Fu Q. Zhang X. Yu P. Zhou S. Wang Y. Zhang J. Chen S. Zhang H. Zhu Q. Qin T. A pan-cancer analysis of potassium channel tetramerization domain containing 12 in human cancer. Sci. Rep. 2023 13 1 13898 10.1038/s41598‑023‑41091‑8 37626178
    [Google Scholar]
  63. Sun M. Yan H. Zhang A. Jin Y. Lin C. Luo L. Wu B. Fan Y. Tian S. Cao X. Wang Z. Luo J. Yang Y. Jia J. Zhou P. Tang Q. Jones C.S. Varshney R.K. Srivastava R.K. He M. Xie Z. Wang X. Feng G. Nie G. Huang D. Zhang X. Zhu F. Huang L. Milletdb: A multi-omics database to accelerate the research of functional genomics and molecular breeding of millets. Plant Biotechnol. J. 2023 21 11 2348 2357 10.1111/pbi.14136 37530223
    [Google Scholar]
  64. Tan H. Yan X. Chen Y. Huang G. Luo L. Li W. Lan W. Chen C. Xi X. A real-world pharmacovigilance study of drug-induced QT interval prolongation: Analysis of spontaneous reports submitted to FAERS. Front. Cardiovasc. Med. 2024 11 1363382 10.3389/fcvm.2024.1363382 38803662
    [Google Scholar]
  65. Liang X. Xiao H. Li H. Chen X. Li Y. Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: A safety analysis of clinical trials and FDA pharmacovigilance system. Front. Immunol. 2024 15 1396752 10.3389/fimmu.2024.1396752 38745663
    [Google Scholar]
  66. Li Y. Li H. Xiang Z. Alpelisib-related adverse events: The FDA adverse event reporting system database (FAERS) pharmacovigilance study. Heliyon 2024 10 6 27599 10.1016/j.heliyon.2024.e27599 38510044
    [Google Scholar]
  67. Zhu J. Li J. Zheng Y. Gao S. He Z. Qiu K. Yu X. Wu J. Facial palsy induced by immune checkpoint blockade: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data. Int. Immunopharmacol 2023 125 Pt B 111184 10.1016/j.intimp.2023.111184
    [Google Scholar]
  68. Bomze D. Meirson T. Ali O.H. Goldman A. Flatz L. Habot-Wilner Z. Ocular adverse events induced by immune checkpoint inhibitors: A comprehensive pharmacovigilance analysis. Ocul. Immunol. Inflamm. 2022 30 1 191 197 10.1080/09273948.2020.1773867 32749899
    [Google Scholar]
  69. Zhao B. Zhang X. Chen M. Wang Y. A real-world data analysis of acetylsalicylic acid in FDA adverse event reporting system (FAERS) database. Expert Opin. Drug Metab. Toxicol. 2023 19 6 381 387 10.1080/17425255.2023.2235267 37421631
    [Google Scholar]
  70. Cao Z. Wu Y. Li Q. Li Y. Wu J. A causal relationship between childhood obesity and risk of osteoarthritis: Results from a two-sample mendelian randomization analysis. Ann. Med. 2022 54 1 1636 1645 10.1080/07853890.2022.2085883 35703935
    [Google Scholar]
  71. Kuppa A. Tripathi H. Al-Darraji A. Tarhuni W.M. Abdel-Latif A. C-reactive protein levels and risk of cardiovascular diseases: A two-sample bidirectional mendelian randomization study. Int. J. Mol. Sci. 2023 24 11 9129 10.3390/ijms24119129 37298077
    [Google Scholar]
  72. Lawler T. Andersen S.W. Serum 25-hydroxyvitamin D and cancer risk: A systematic review of mendelian randomization studies. Nutrients 2023 15 2 422 10.3390/nu15020422 36678292
    [Google Scholar]
  73. Kojima T. Akishita M. Drug-induced dementia. Jpn. J. Clin. Med. 2016 74 3 510 514 27025096
    [Google Scholar]
  74. Koutroumani M. Daniilidou M. Giannakouros T. Proitsi P. Liapi D. Germanou A. Nikolakaki E. Tsolaki M. The deletion variant of α2b-adrenergic receptor is associated with decreased risk in Alzheimer’s disease and mild cognitive impairment. J. Neurol. Sci. 2013 328 1-2 19 23 10.1016/j.jns.2013.02.003 23499426
    [Google Scholar]
  75. Liu S. Yuan X. Su H. Liu F. Zhuang Z. Chen Y. ZNF384: A potential therapeutic target for psoriasis and Alzheimer’s disease through inflammation and metabolism. Front. Immunol. 2022 13 892368 10.3389/fimmu.2022.892368 35669784
    [Google Scholar]
  76. Ramirez L.M. Goukasian N. Porat S. Hwang K.S. Eastman J.A. Hurtz S. Wang B. Vang N. Sears R. Klein E. Coppola G. Apostolova L.G. Common variants in ABCA7 and MS4A6A are associated with cortical and hippocampal atrophy. Neurobiol. Aging 2016 39 82 89 10.1016/j.neurobiolaging.2015.10.037 26923404
    [Google Scholar]
  77. de Luna N. Carbayo Á. Dols-Icardo O. Turon-Sans J. Reyes-Leiva D. Illan-Gala I. Jericó I. Pagola-Lorz I. Lleixà C. Querol L. Rubio-Guerra S. Alcolea D. Fortea J. Lleó A. Cortés-Vicente E. Rojas-Garcia R. Neuroinflammation-related proteins NOD2 and Spp1 are abnormally upregulated in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2023 10 2 200072 10.1212/NXI.0000000000200072 36460480
    [Google Scholar]
  78. Bondon-Guitton E. Sommet A. Montastruc J. French Association of Regional Pharmacovigilance Centres Confusion, a rather serious adverse drug reaction with valproic acid: A review of the French pharmacovigilance database. Pharmacopsychiatry 2009 42 2 61 65 10.1055/s‑0028‑1102912 19308880
    [Google Scholar]
  79. Sharma V.K. Singh T.G. CREB: A multifaceted target for Alzheimer’s disease. Curr. Alzheimer Res. 2021 17 14 1280 1293 10.2174/1567205018666210218152253 33602089
    [Google Scholar]
  80. Adhikarla S.V. Jha N.K. Goswami V.K. Sharma A. Bhardwaj A. Dey A. Villa C. Kumar Y. Jha S.K. TLR-mediated signal transduction and neurodegenerative disorders. Brain Sci. 2021 11 11 1373 10.3390/brainsci11111373 34827372
    [Google Scholar]
  81. Wang L. Xiaokaiti Y. Wang G. Xu X. Chen L. Huang X. Liu L. Pan J. Hu S. Chen Z. Xu Y. Inhibition of PDE2 reverses beta amyloid induced memory impairment through regulation of PKA/PKG-dependent neuro-inflammatory and apoptotic pathways. Sci. Rep. 2017 7 1 12044 10.1038/s41598‑017‑08070‑2 28935920
    [Google Scholar]
  82. Sun F. Zhou K. Tian K. Zhang X. Liu W. Wang J. Zhong C. Qiu J. Zha D. Atrial natriuretic peptide promotes neurite outgrowth and survival of cochlear spiral ganglion neurons in vitro through NPR-A/cGMP/PKG signaling. Front. Cell Dev. Biol. 2021 9 681421 10.3389/fcell.2021.681421 34268307
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673378809250707043350
Loading
Post-marketing Safety Surveillance of Drug-induced Dementia: Utilizing Signal Detection and Mendelian Randomization in Spontaneous Reports
Bentham Science Publishers ; https://doi.org/10.2174/0109298673378809250707043350
/content/journals/cmc/10.2174/0109298673378809250707043350
/content/journals/cmc/10.2174/0109298673378809250707043350
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: molecular pathways ; mendelian randomization ; drug-induced dementia ; pharmacovigilance ; signal detection ; Post-marketing surveillance

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test